Polaryx Therapeutics, Inc. PLYX
1.95 USD +0.08 (+4.28%)
At closeNov 11, 2026, 4:00 PM EST
1.94 -0.01 -0.51%
After hours · Nov 11, 4:00 PM ET
1.90 Day range 1.95
1.69 52-week range 48.91
- YTD
- -94.43%
- 1 year
- -94.43%
News
benzinga.com Polaryx Therapeutics Announces Activation Of First Clinical Trial Site For SOTERIA For Eligible Pediatric Participants Polaryx Therapeutics, Inc. (NASDAQ:PLYX) ("Polaryx" or the "Company"), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare pediatric lysosomal storage…
globenewswire.com Polaryx Therapeutics Activates First Clinical Trial Site for SOTERIA Phase 2 Basket Trial of PLX-200 Boys Town National Research Hospital in Nebraska becomes first activated site in study targeting four rare pediatric lysosomal storage disorders and has now initiated patient screening as Polaryx…
benzinga.com Why Webuy Global Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket Webuy Global shares jumped 15% premarket after H1 revenue nearly doubled to $14.31M and net loss narrowed; Game Your Game led gainers, Masonglory fell.
benzinga.com This Vail Resorts Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday Wall Street analysts changed outlook on top names. Check analyst ratings page for all changes. See what analysts think of MTN stock.
benzinga.com Raymond James Initiates Coverage On Polaryx Therapeutics with Strong Buy Rating, Announces Price Target of $6 Raymond James analyst Tiago Fauth initiates coverage on Polaryx Therapeutics (NASDAQ:PLYX) with a Strong Buy rating and announces Price Target of $6.
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers Replimune Group (NASDAQ:REPL) shares increased by 134.6% to $12.69 during Friday's pre-market session. Moleculin Biotech (NASDAQ:MBRX) shares increased by 17.64% to $1.2. The market value of…- benzinga.com LUCID CAPITAL MARKETS Initiates Coverage On Polaryx Therapeutics with Buy Rating, Announces Price Target of $7 LUCID CAPITAL MARKETS analyst Dev Prasad initiates coverage on Polaryx Therapeutics (NASDAQ:PLYX) with a Buy rating and announces Price Target of $7.
- benzinga.com HC Wainwright & Co. Initiates Coverage On Polaryx Therapeutics with Buy Rating, Announces Price Target of $7 HC Wainwright & Co. analyst Raghuram Selvaraju initiates coverage on Polaryx Therapeutics (NASDAQ:PLYX) with a Buy rating and announces Price Target of $7.
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session Gainers Catheter Precision (AMEX:VTAK) shares moved upwards by 34.7% to $0.96 during Tuesday's after-market session. The company's market cap stands at $2.0 million. Ironwood Pharmaceuticals…
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session 
benzinga.com Why Polaryx Therapeutics Stock Is Surging On Thursday? Polaryx Therapeutics (NASDAQ: PLYX) stock climbs on Thursday following a $10M private placement to launch its Phase 2 SOTERIA trial for rare lysosomal storage disorders.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session - benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
benzinga.com Polaryx Therapeutics Says FDA Grants Fast Track Designation To PLX-200 For Treatment Of JNCL/CLN3 Disease, Krabbe Disease, And Sandhoff Disease Polaryx Therapeutics, Inc. (NASDAQ:PLYX), a clinical-stage biotechnology company developing disease-modifying therapies for rare pediatric LSDs, today announced that the U.S. Food and Drug…- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com Polaryx Therapeutics Says FDA Grants Fast Track Designation To PLX-200 For Treatment Of Late-Infantile Neuronal Ceroid Lipofuscinosis Regulatory milestone supports advancement of the SOTERIA Phase 2 basket trial evaluating PLX‑200 across multiple lysosomal storage disorders PARAMUS, NJ, March 17, 2026 (GLOBE NEWSWIRE) -- Polaryx…- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
benzinga.com Maxim Group Initiates Coverage On Polaryx Therapeutics with Buy Rating, Announces Price Target of $10 Maxim Group analyst Jason McCarthy initiates coverage on Polaryx Therapeutics (NASDAQ:PLYX) with a Buy rating and announces Price Target of $10.- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga.com Dow Gains 100 Points; Analog Devices Posts Upbeat Q1 Earnings - benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com Dow Falls 250 Points; Becton Dickinson Posts Upbeat Earnings 
benzinga.com Strategy, Bitmine Immersion Technologies And Other Big Stocks Moving Lower In Monday's Pre-Market Session U.S. stock futures were lower this morning, with the Nasdaq 100 futures falling around 100 points on Monday.
benzinga.com Why STMicroelectronics Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket 
benzinga.com Why Teradyne Shares Are Trading Higher By Over 22%; Here Are 20 Stocks Moving Premarket